Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses.

Das R, Komorowski R, Hessner MJ, Subramanian H, Huettner CS, Cua D, Drobyski WR.

Blood. 2010 Jun 24;115(25):5249-58. doi: 10.1182/blood-2009-11-255422. Epub 2010 Apr 9.

3.
4.

Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.

Sprangers B, Van Wijmeersch B, Fevery S, Waer M, Billiau AD.

Nat Clin Pract Oncol. 2007 Jul;4(7):404-14. Review.

PMID:
17597705
5.

[Target antigens for graft-versus-host disease (GVHD) and graft-versus-leukemia/tumor (GVL/T)].

Tanaka J.

Nihon Rinsho. 2003 Sep;61(9):1512-9. Review. Japanese.

PMID:
14515717
6.

Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.

Warren EH, Deeg HJ.

Tissue Antigens. 2013 Apr;81(4):183-93. doi: 10.1111/tan.12090. Review.

7.

Graft-versus-leukemia effect and its clinical implications.

Imamura M, Hashino S, Tanaka J.

Leuk Lymphoma. 1996 Nov;23(5-6):477-92. Review.

PMID:
9031079
8.

Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Li JM, Giver CR, Lu Y, Hossain MS, Akhtari M, Waller EK.

Immunotherapy. 2009 Jul;1(4):599-621. Review.

9.

The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease.

Cooke KR, Olkiewicz K, Erickson N, Ferrara JL.

J Endotoxin Res. 2002;8(6):441-8. Review.

PMID:
12697087
10.

Prevention of GVHD without losing GVL effect: windows of opportunity.

Zhang P, Chen BJ, Chao NJ.

Immunol Res. 2011 Apr;49(1-3):49-55. doi: 10.1007/s12026-010-8193-7. Review.

PMID:
21136200
11.

Graft-versus-leukemia effects of transplantation and donor lymphocytes.

Kolb HJ.

Blood. 2008 Dec 1;112(12):4371-83. doi: 10.1182/blood-2008-03-077974. Review.

12.

Graft-versus-leukemia reactions in allogeneic chimeras.

Kolb HJ, Schmid C, Barrett AJ, Schendel DJ.

Blood. 2004 Feb 1;103(3):767-76. Epub 2003 Sep 4. Review.

14.

Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.

Sinkovics JG.

Acta Microbiol Immunol Hung. 2010 Dec;57(4):253-347. doi: 10.1556/AMicr.57.2010.4.2. Review.

PMID:
21183421
15.

Insights into the pathogenesis of GvHD: what mice can teach us about man.

Hülsdünker J, Zeiser R.

Tissue Antigens. 2015 Jan;85(1):2-9. doi: 10.1111/tan.12497. Epub 2014 Dec 23. Review.

PMID:
25532439
16.

Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL.

Nash RA, Storb R.

Curr Opin Immunol. 1996 Oct;8(5):674-80. Review.

PMID:
8902393
17.

Next-generation leukemia immunotherapy.

Vincent K, Roy DC, Perreault C.

Blood. 2011 Sep 15;118(11):2951-9. doi: 10.1182/blood-2011-04-350868. Epub 2011 Jul 6. Review.

18.

Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia.

Parmar S, Fernandez-Vina M, de Lima M.

Curr Opin Hematol. 2011 Mar;18(2):98-104. doi: 10.1097/MOH.0b013e328343b858. Review.

PMID:
21245756
19.

Minor histocompatibility antigens: past, present, and future.

Spierings E.

Tissue Antigens. 2014 Oct;84(4):374-60. doi: 10.1111/tan.12445. Review.

PMID:
25262921
20.

Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.

Talmadge JE.

Int Immunopharmacol. 2003 Aug;3(8):1121-43. Review.

PMID:
12860168

Supplemental Content

Support Center